A phase IV, open-label, randomized study to compare the efficacy and safety of Epivir/Ziagen [lamivudine/abacavir]/Zerit [stavudine] (3TC/ABC/d4T) versus Epivir/Ziagen/Sustiva [efavirenz] (3TC/ABC/EFV) versus Epivir/Ziagen/Agenerase/Norvir [amprenavir/ritonavir](3TC/ABC/APV/RTV) for 96 weeks in the treatment of HIV-1 infected subjects who are antiretroviral therapy naive

Trial Profile

A phase IV, open-label, randomized study to compare the efficacy and safety of Epivir/Ziagen [lamivudine/abacavir]/Zerit [stavudine] (3TC/ABC/d4T) versus Epivir/Ziagen/Sustiva [efavirenz] (3TC/ABC/EFV) versus Epivir/Ziagen/Agenerase/Norvir [amprenavir/ritonavir](3TC/ABC/APV/RTV) for 96 weeks in the treatment of HIV-1 infected subjects who are antiretroviral therapy naive

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2005

At a glance

  • Drugs Amprenavir/ritonavir; Efavirenz; Lamivudine/abacavir; Stavudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top